Solid-pseudopapillary tumor of the pancreas: Clinical experience and literature review

Table 1 Demographic and clinicopathologic data from seven patients with solid-pseudopapillary tumor of the pancreas.

Case	Age (yr)	Sex	Presentation	Site	Size (cm)	Local Invasion/metastasis	Operation	Follow up (yr)
1	13	F	Mass	Tail	20	Liver and Spleen	DP	REC (14)
2	19	F	Hemoperi- toneum	Tail	8	Pancreas	DP	AW (0.5)
3	19	F	Mass	Head	10	Pancreas	Whipple	AW (1)
4	29	F	Asympto- matic	Tail	11	Spleen	DP+S	AW (3)
5	42	F	Abdominal discomfort	Body + Tail	15	Pancreas and spleen	DP + S	AW (14)
6	45	F	Asympto-matic	Body	5	Nil	DP	AW (2)
7	50	M	Abdominal discomfort	Head	5	Pancreas	PD	AW (6)

OP: operation; DP: distal pancreatectomy; S: splenectomy; PD: pancreaticoduodenectomy; REC: recurrence; AW: alive and well.

Table 2 Immunostaining study of SPT of the pancreas.

Case	Lesion	AAT	ACT	NSE	Vim	CTK	Chr	SYN	Est	Pro
1	M	Posi	Posi	Posi	Posi	-	Neg	Neg	-	-
2	P	Posi	-	Posi	Posi	Neg	Neg	Neg	-	-
3	P	Posi	-	Posi	Posi	-	Neg	-	Neg	Neg
4	P	-	Posi	Posi	Posi	Posi	Posi	-	-	-
5	-	-	-	-	-	-	-	-	-	-
6	P	Posi	-	Posi	Posi	-	Neg	Neg	-	-
7	P	Posi	-	Posi	Posi	Posi	Neg	Neg	-	-

M: Metastatic liver lesion; P: Primary tumor; Posi: Positive: Neg: Negative; AAT: α₁-antitrypsin; ACT: α₁-antichymotrypsin; NSE: neuron-specific enolase; Vim: vimentin; CTK: cytokeratin; Chr: chromogranin; SYN: synaptophysin; Est: estrogen; Pro: progesterone.